Leonard S. Schleifer, Board Co-Chair, President, and CEO of Regeneron Pharmaceuticals (REGN), has demonstrated a clear selling bias in recent insider transactions, with no buys and 20 sales recorded in the latest filings. Since May 2024, Schleifer has executed multiple sales totaling over $95.9 million, including a $22.2 million transaction on May 14, followed by a $7.7 million sale the next day. The selling activity intensified in June, with a $17.7 million disposition on June 11 and a $15.1 million sale on June 12. Notably, Schleifer’s largest transactions occurred in December 2025, including a $108.8 million sale on December 9 and a $22 million sale on December 31, though these may reflect planned dispositions rather than discretionary trades.
Over the course of 27 reported transactions, Schleifer has sold a total of $355.9 million in REGN shares while purchasing $177.2 million worth, resulting in a net divestment of approximately $178.8 million. The sales have been executed at varying price points, with smaller transactions in the hundreds of thousands and larger disposals in the tens of millions. The absence of recent buys suggests a consistent reduction in his position, though the reasons remain undisclosed in SEC filings. As a long-standing executive at Regeneron, Schleifer’s trading activity provides insight into his equity management strategy, though it does not necessarily indicate a shift in company outlook.
AI-assisted summary